Cardiff Health Partners (CHP), a strategic partnership between Cardiff University, Cardiff and Vale University Health Board and Velindre University NHS Trust, has appointed Rachel Savery as its interim Managing Director.
Velindre Cancer Service colleagues have been recognised for their outstanding contributions to healthcare innovation at last week’s MediWales Innovation Awards.
Accession Therapeutics’ ATTEST trial is a first-in-human Phase 1 trial in solid tumour patients, testing TROCEPT-01 (also known as ATTR-01). The trial is being delivered by Velindre University NHS Trust and Cardiff and Vale University Health Board.
Emma Williams, Senior Research Nurse Manager at the Velindre Cancer Service, has become the first nurse to be accepted onto the Cancer Research UK Women in Influence programme.